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Background: Lithium has been reported in some, but not all, studies to be associated with reduced risks of suicide
death or suicidal behavior. The objective of this nonrandomized cohort study was to examine whether lithium was
associated with reduced risk of suicide death in comparison to the commonly-used alternative treatment, valproate.
Methods: A propensity score-matched cohort study was conducted of Veterans Health Administration patients
(n=21,194/treatment) initiating lithium or valproate from 1999-2008.
Results: Matching produced lithium and valproate treatment groups that were highly similar in all 934 propensity
score covariates, including indicators of recent suicidal behavior, but recent suicidal ideation was not able to be
included. In the few individuals with recently diagnosed suicidal ideation, a significant imbalance existed with
suicidal ideation more prevalent at baseline among individuals initiating lithium than valproate (odds ratio (OR)
1.30, 95% CI 1.09, 1.54; p=0.003). No significant differences in suicide death were observed over 0-365 days in A) the
primary intent-to-treat analysis (lithium/valproate conditional odds ratio (cOR) 1.22, 95% CI 0.82, 1.81; p=0.32); B)
during receipt of initial lithium or valproate treatment (cOR 0.86, 95% CI 0.46, 1.61; p=0.63); or C) after such
treatment had been discontinued/modified (OR 1.51, 95% CI 0.91, 2.50; p=0.11). Significantly increased risks of
suicide death were observed after the discontinuation/modification of lithium, compared to valproate, treatment
over the first 180 days (OR 2.72, 95% CI 1.21, 6.11; p=0.015).
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Conclusions: In this somewhat distinct sample (a predominantly male Veteran sample with a broad range of psychiatric
diagnoses), no significant differences in associations with suicide death were observed between lithium and valproate
treatment over 365 days. The only significant difference was observed over 0-180 days: an increased risk of suicide death,
among individuals discontinuing or modifying lithium, compared to valproate, treatment. This difference could reflect
risks either related to lithium discontinuation or higher baseline risks among lithium recipients (i.e., confounding) that
became more evident when treatment stopped. Our findings therefore support educating patients and providers about
possible suicide-related risks of discontinuing lithium even shortly after treatment initiation, and the close monitoring of
patients after lithium discontinuation, if feasible. If our findings include residual confounding biasing against lithium,
however, as suggested by the differences observed in diagnosed suicidal ideation, then the degree of beneficial
reduction in suicide death risk associated with active lithium treatment would be underestimated. Further research is
urgently needed, given the lack of interventions against suicide and the uncertainties concerning the degree to which
lithium may reduce suicide risk during active treatment, increase risk upon discontinuation, or both.
Keywords: Suicide, Lithium, Valproate, Veterans, Veterans Health Administration, Propensity score, Matching,
Discontinuation, Intent-to-treat, Suicidal behaviorBackground
Preventing suicide is a global imperative [1], a need for
Veterans [2] (especially those with mental health condi-
tions [3]), and a priority for the Veterans Health Admin-
istration (VHA) [4]. The psychiatric medication lithium
has been previously reported to be associated with
uniquely large reductions in risks of suicide death and
suicidal behavior [5-7]. Many studies, however, have
been nonrandomized, and a 2013 randomized trial
meta-analysis did not note any statistically significant
differences in suicide deaths between lithium and spe-
cific comparison medications [8]. Despite the inclusion
of 35 trials, however, just 4 suicide deaths were observed
among patients assigned to lithium and 9 suicide deaths
among patients assigned to other medications [8]. In
contrast, lithium was associated with a significant, and
quite substantial, reduction in suicide death compared
to placebo (Odds Ratio (OR) 0.13, 95% CI 0.03, 0.66,
p = 0.01). A significantly lower risk of suicide death was also
noted in a trial of lithium augmentation versus placebo aug-
mentation of antidepressant treatment in major depression,
but again was based on extremely few outcomes (3 suicide
deaths, all receiving placebo augmentation) [9].
The specific question of whether significant differences
in suicide death or suicidal behavior exist between lith-
ium and the anticonvulsant valproate is of particular im-
portance. Valproate is a more commonly-used treatment
alternative in the United States than lithium for patients
with mood disorders, particularly bipolar disorder. A
prominent 2003 nonrandomized study of health main-
tenance patients with bipolar disorder has only added
interest in this comparison by reporting that lithium was
associated with statistically significant, > 60% lower risks
of suicide death and suicidal behavior compared to
valproate [6]. The 2013 randomized trial meta-analysis,
however, was unable to evaluate whether differencesbetween lithium and valproate exist in the risk of suicide
death, since no suicide deaths were observed in any of the
five trials comparing these medications [8]. The meta-
analysis did report nonsignificant differences in suicidal
behavior between lithium and valproate (OR 0.64, 95% CI
0.30, 1.36, p = 0.24). Valproate is, however, one of many
antiepileptic medications that now carries a US Food and
Drug Administration-mandated warning stating that anti-
epileptic medications increase the risks of suicidal
thoughts or behavior (for patients taking these medications
for any indication). We therefore decided to conduct a
nonrandomized cohort study of patients with mental
health disorders initiating lithium and valproate using the
VHA’s large and detailed clinical databases.
Nonrandomized studies can provide the large samples
needed to more easily determine associations between
treatments and suicide-related outcomes (especially suicide
death). Many previous nonrandomized studies, however,
have suffered from substantial methodological limitations,
lacking adjustment for many potential confounders, active
controls, incident-user designs, uniform follow-up, or
intent-to-treat designs [10]. In particular, concerns exist
that previous nonrandomized studies may have been con-
founded through preferential prescription of lithium to pa-
tients at low [11] or lower [10] risk of suicide death. It is
possible, however, although unestablished, that prescriber
behavior has changed over the past 15 years given well-
publicized meta-analyses [12,13], treatment guidelines [14],
and high-profile studies [6] reporting that lithium treat-
ment may be associated with distinct reductions in suicide
death or suicidal behavior.
Using data from this more recent period in which the dir-
ection of any confounding between lithium and comparison
treatments may have changed, we also sought to reduce the
amount of any confounding through methods intended to
approximate some of the strengths of randomized trials. In
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included: 1) matching patients based on a propensity score
[15] of extensive scope and detail [16], and 2) deriving
intent-to-treat and post-discontinuation risk estimates [17].
Propensity score matching can permit a greater number of
covariates than previously possible to be controlled, creat-
ing treatment groups closely similar in prevalence for nu-
merous covariates (similar, in some respects, to a trial).
Intent-to-treat estimates ensure that risks arising after treat-
ment discontinuation are considered in judgments of treat-
ment effectiveness. Combining this more recent data with
these methodological approaches, we conducted the largest
cohort study to date examining whether the risk of suicide
death differs between patients initiated on lithium com-
pared to valproate.
Methods
Data sources
Demographic, inpatient and outpatient mental and non-
mental health treatment records, and outpatient pharmacy
prescription data was obtained from the VHA’s National
Psychosis and Depression Registries [18] (linked, de-
identified healthcare databases of all VHA patients since
1997 with at least one psychotic or depressive disorder
diagnosis). This study involved no prospective enrollment
of human subjects. Treatment exposure, covariates, and
outcome were characterized by information previously re-
corded during use of the VHA by patients. As with other
large healthcare database outcome studies, no informed
consent was obtained. This study was approved by the In-
stitutional Review Boards of the Bedford and Ann Arbor
Veterans Affairs Medical Centers.
Study cohort
Incident users (> 6 months of no lithium or valproate use)
with recent VHA utilization (past year and a previous
year) were identified among all patients with mood or
psychotic disorders within the past 30 days receiving at
least one outpatient prescription for lithium or valproate
from April 1999 to December 2008. These broad diagnos-
tic inclusion criteria (Additional file 1: Appendix 1) were
chosen to maximize statistical power, given the compara-
tively few suicides expected, even in a large cohort, over a
fixed one-year follow-up period, and to facilitate the evalu-
ation of lithium and valproate as broadly useful suicide
preventatives. Prior research suggests that any effective-
ness of lithium against suicide death is not restricted to
patients with bipolar disorder [9,19]. Individuals with po-
tentially nonpsychiatric indications for treatment were
excluded (epilepsy, migraine headache, or neuropathy
diagnoses in the past 30 days; dementia medication use in
the past 180 days; cancer, dementia, skull fracture or trau-
matic brain injury diagnosis in the past year; traumatic
brain injury treatment, home care, or hospice care in thepast year; or any nursing home residence or inpatient re-
habilitation in the past 2 years). Patients were also ex-
cluded if they had started their mood stabilizer on an “as
needed” basis (as indicated by receiving an initial prescrip-
tion designated “prn”) or both mood stabilizers simultan-
eously (Figure 1).
Exposure determination
Receipt of lithium or valproate was determined by out-
patient prescription fills. The primary analysis examined
all individuals initiating either lithium or valproate treat-
ment and followed these individuals until end of follow-
up (365 days), suicide death, or death from other causes
(i.e., an “intent-to-treat” analysis). As clarification, our
study did not examine primary and secondary outcomes
per se (the focus consistently being on suicide death),
but we did perform primary (intent-to-treat) and sec-
ondary analyses of this outcome. Additional secondary
analyses examined briefer follow-up times and/or strati-
fied follow-up time by whether individuals were still
receiving initial treatment. Individuals were identified
as “still receiving initial treatment” if they had not
switched to or added the other treatment, nor discontin-
ued the initial treatment (experienced a ≥ 15 day gap be-
tween outpatient prescriptions, adjusted for early refills).
All other follow-up time was classified as occurring
during the period when individuals had “stopped/modi-
fied” initial treatment. Since this stopper/modifier group
included individuals subsequently resuming either treat-
ment, we also analyzed suicide death risks for individuals
over 0–180 days which had stopped initial treatment
and not resumed either treatment before suicide, other
mortality, or the end of follow-up. Risks observed after
treatment discontinuation may reflect risks related to
discontinuation of the medication (e.g., “rebound”
mania or depression), but may also reflect differences in
baseline risk between the treatment groups (i.e., con-
founding) or differences in selection occurring during
follow-up [17].
Outcome
Date and cause of death (suicide) was obtained from Na-
tional Death Index files [20] for 1999–2009 using previ-
ously established definitions (International Classification
of Diseases, Tenth Revision, codes X60–X84, Y87.0, and
U03) [21].
Propensity score modeling
An extensive set of 934 baseline covariates was derived
(Table 1 and Additional file 1: Appendix 2) from VHA da-
tabases reflecting demographics, diagnoses, general VHA
mental and nonmental health healthcare utilization [16],
hospitalizations, clinic use, diagnostic testing, current
and recent prescriptions (Additional file 1: Appendix 3),
ALL VHA PATIENTS
w/ MOOD or PSYCHOTIC DISORDERS
RECEIVING Li or VAL, 1999-2008
TOTAL= 304,627
Lithium (Li)= 64,850 Valproate (VAL)= 239,777
INCIDENT USERS OF Li OR VAL
TOTAL=242,087
Li = 45,706 (71.6%) VAL = 196,381 (81.6%)
INCIDENT USERS w/ ADEQUATE VHA USE
TOTAL= 177,984
Li = 30,378 (46.8%) VAL = 147,596 (61.6%)
INCIDENT USERS w/ ACTIVE
MOOD or PSYCHOSIS DX
TOTAL=120,058
Li = 25,045 (38.6%) VAL = 95,013 (39.6%)
INCIDENT PRESUMED PSYCHIATRIC
USERS
TOTAL=108,364
Li = 23,928 (36.9%) VAL = 84,436 (35.2%)
FINAL COHORT:
Clinic-Attending Outpatients
w/o Serious Conditions
potentially affecting Nervous System
TOTAL= 93,335
Li = 21, 468 (33.1%) VAL = 71, 887 (30.0%)
EXCLUDED: PREVALENT USERS
TOTAL= 62,540 (20.5%)
Li = 18,396 (28.4%) VAL = 44,144 (18.4%)
EXCLUDED: INADEQUATE RECENT VHA USE
TOTAL= 64,113 (26.5%)
Li = 15,328 (33.5%) VAL = 48,785 (24.8%)
EXCLUDED: NO MOOD or PSYCHOSIS DX
w/in PRIOR 30d
TOTAL= 57,916 (32.5%)
Li = 5,333 (17.6%) VAL = 52,583 (35.6%)
EXCLUDED: DUAL USERS, PRN USERS, or
POTENTIALLY NONPSYCHIATRIC USERS
TOTAL= 11,694 (9.8%)
Li = 1,116 (4.3%) VAL = 10,578 (11.3%)
EXCLUDED: SERIOUSLY ILL or POSSIBLY
NEUROLOGICALLY SERIOUSLY ILL
PATIENTS
(Receiving home care, or suffering Cancer,
Dementia, TBI/paralysis/other select
neurologic conditions)
TOTAL= 15,029 (13.9%)
Li = 2,460 (10.3%) VAL = 12,549 (14.9%)
Figure 1 Flowchart of Study Cohort Derivation.
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level) suicide risk (Additional file 1: Appendix 2), and
prior mood stabilizer treatment. Data in these categories
were often modeled over several time periods or with
flexible forms (multiple indicator variables). This ap-
proach follows the general aims of “high-dimensional”
propensity score methodology [16,22], but did notinclude automated variable generation or selection. In-
stead, a number of covariates in each domain (Table 1)
were generally included, since the full determinants of
suicide risk are not well understood, although covariates
with a substantial association with treatment exposure
(i.e., with which treatment a patient receives) were indi-
vidually evaluated and removed if they were judged
Table 1 Summary of variables included in the propensity scorea
Type of patient characteristic Covariates included
General Covariates
Demographics 49 Total Covariates including: Age (5-year categories), Sex, self-reported Race, Ethnicity, Marital Status,
Income, Disability Status, Distance to VHA facility, Urban/Rural hospital location, and Year of Medication Start
Psychiatric Covariatesb
Presenting Diagnosis 9 Variables, including Bipolar I, Bipolar II, Bipolar NOS, Major Depression, Depression NOS, Schizophrenia,
Schizoaffective Disorder and Other Psychoses
General Utilization 74 Covariates, including Total VHA Mental Health (MH) Provider Visits x 6 time periods, Total MH
hospitalizations x 2 time periods, and Total Diagnostic Interviews, Total Medication Management Visits,
Total Individual Psychotherapy Visits, Total Group Psychotherapy Visits (all x 2 time periods), and Total
Current MH Medications, Recently Discontinued MH medications, and Possibly Discontinued MH medications
Comorbid Diagnoses 46 Covariates including PTSD, Other Anxiety Disorders, Adjustment Disorders, Personality Disorders,
Somatoform Disorders, Impulse Control Disorders, Sleep Disorders, Eating Disorders, Sexual Disorders,
Delusional Disorder, ADHD, Development Disorders, Cognitive Disorder NOS, and Dissociative Disorder
Comorbid Substance Abuse Diagnoses 41 Covariates, including 4 Covariates (Abuse, Dependence, Remission from Abuse, and Remission from
Dependence for each of the following: Alcohol, Amphetamines, Cocaine, Marijuana, Opioids, Sedatives,
Other), with other covariates for Hallucinogen Abuse/Dependence/Remission, Combined Drug Dependence
and Remission from Combined Drug Dependence, with and without opioids, Unspecified Dependence,
and Alcohol intoxication and Alcohol or Drug psychoses
Suicidal Behavior Diagnoses 9 Covariates, designating if Suicidal Behavior was diagnosed during Nonmental Health hospitalizations,
Mental Health hospitalizations, or as an Outpatient, x 3 time periods (0-30 days, 31-180 days, or 181-365
days prior to Lithium or Valproate initiation)
Psychiatric Hospitalizations 10 Covariates, including Covariates designating whether patient was an Inpatient on Start Date,
discharged within the last 7 days, 8-30 days, 31-180 days, and 181-365 days, the type of latest hospitalization
(Psychiatric, Substance Abuse, Residential/Day program, Domiciliary), and whether any hospitalizations in
the last year involved an AMA (Against Medical Advice) discharge
Specific Outpatient Utilization 48 Covariates (all modeled as 0 visits, 1 visits, or 2+ visits): General Mental Health clinic, Psychiatry visits,
Psychotherapy visits, Substance Use Disorder visit, Primary Care Mental Health clinic, Health Care for
Homeless Veterans, and Substance Abuse and non-Substance Abuse visits, x 2 time periods (0-180 days
and 181-365 days)
Current Medications 24 Covariates, including Olanzapine, Risperidone, Quetiapine, Ziprasidone, Aripiprazole, Clozapine, First
Generation Antipsychotics, Other Mood Stabilizers, SSRIs, SNRIs, Bupropion, Mirtazapine, TCAs, MAOIs,
Benzodiazepines, other Hypnotics, Stimulants, Substance Abuse treatments, and other medications
Recent Medications 24 covariates, designating prescriptions received in last 180 days for same medication categories as
“Current Medications,” but for which the patients’ prescribed supply does not extend to the Lithium/
Valproate start date
Prior Treatment History Prior treatment with Any Mood Stabilizer, Prior treatment with Lithium or Valproate
Geographic Suicide Risk 5 variables designating quintiles of Age-Adjusted State Suicide Rates (2000-2007)
Nonpsychiatric Variables of Possible Particular Relevance to Suicide Riskb
Nonpsychiatric Diagnoses 7 covariates, including any Acute Injury, any Fracture, Blood Vessel injury, Internal injuries, Open Wounds,
Poisoning, Inhalation/Drowning/Asphyxiation injury
Nonpsychiatric Utilization 6 covariates, including Pain Clinic visits (0, 1, 2+) x 2 time periods
Nonpsychiatric Medications 4 variables, including current Opiate Pain Medicine, recent Opiate Pain Medicine, and 2 types of overdose antidotes
Also Includedb:
Numerous covariates designating Nonpsychiatric Diagnoses, Nonpsychiatric Hospitalizations, Nonpsychiatric VHA Utilization (both the general
amount of Nonpsychiatric VHA care received and specific clinics attended and/or care received ), Nonpsychiatric Medications
(current and recent), and Nonpsychiatric Diagnostic Tests.
3 covariates recording prior VHA pharmacy use (any prior use, use in the last 180 days, and use in the last 365 days) were also included to
help balance the extensiveness of pharmacy records among recipients.
aPrevalence of each covariate balanced within a standardized difference of < 0.018 in final matched cohort.
bAll covariates except Demographics relate to care and/or diagnoses made by providers in the VHA health system.
ADHD = Attention Deficit Hyperactivity Disorder; AMA = Against Medical Advice; MAOI = Monoamine Oxidase Inhibitor; MH = Mental Health; NOS = “Not
Otherwise Specified”; PTSD = Post-Traumatic Stress Disorder; SNRI = Serotonin-Norepinephrine Reuptake Inhibitor; SSRI = Serotonin-Specific Reuptake Inhibitor;
TCA = Tricyclic Antidepressant; VHA = Veterans Health Administration.
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are substantially associated with treatment exposure, but
which are not confounders, can actually increase con-
founding from uncontrolled confounders) [23-26].Statistical methods
The propensity score was calculated by logistic regres-
sion (c statistic = 0.69). We then 1:1 matched patients
initiating lithium and valproate using propensity score
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sity score logit) [27,28], achieving 98.7% matching of
lithium-initiated patients. Balance in the prevalence of
covariates between the treatment groups was assessed
using standardized differences (Table 2). Standardized
differences are equivalent to Cohen’s d effect sizes, with
a difference of ≥ 0.10 often considered as indicating sig-
nificant imbalance [15].
For the analyses of the intent-to-treat cohort and of
individuals still receiving initial treatment, we used con-
ditional logistic regression, whereas for individuals stop-
ping or modifying treatment, ordinary logistic regression
was used since matching was not rigorously preserved.
Several additional analyses were conducted, including
comparing the prevalence between the treatment groups
of diagnostically-coded suicidal ideation (V62.84, a code
for suicidal ideation first introduced in 2005) in the
30 days prior to treatment initiation among the patients
who potentially could receive this diagnosis (the < 50%
of the sample initiating treatment in 2005 or later). We also
compared the suicide risk associated with the treatment
groups prior to matching, conducted a Cox regression ana-
lysis, and conducted a sensitivity analysis matching the
sample with an alternative propensity score. All analyses
were performed using SAS, version 9.3, except the stan-
dardized difference calculations (Microsoft Excel 2007).
Results
A 1:1 propensity-score matched cohort of 42,388 patients
(including 102 suicide deaths over 365 days of follow-up)
was derived from 93,335 incident users of lithium or valpro-
ate (Figure 1). Patients initiating lithium and valproate were
generally balanced even prior to matching on a wide variety
of psychiatric and nonpsychiatric diagnoses, outpatient and
inpatient utilization, and medication covariates: only 17 of
934 covariates (1.8%) exhibited initial standardized differ-
ences of ≥ 0.10 between treatment groups. Table 2 demon-
strates the close balance achieved after propensity score
matching between treatment groups for these 17 initially-
imbalanced covariates (i.e., the italicized covariates in
Table 2) and 14 other important covariates. Similarly close
balance after matching was observed for all other covari-
ates (none of the 934 covariates had a standardized differ-
ence of even 0.018 after matching). Despite the general
balance in most covariates observed between the treat-
ment groups even prior to matching, propensity score
matching led to a substantial reduction in the observed
treatment effect estimate (initial 0–365 day Odds Ratio
[OR] = 1.45 [lithium/valproate], versus 0–365 day Condi-
tional Odds Ratio [cOR] = 1.22 after propensity score
matching) (Additional file 1: Appendix 4).
The treatment groups also displayed very substantial,
but highly similar, rates of stopping or modifying initial
treatment: 47% of patients initiated on both lithium andvalproate were still receiving their initial treatment
at 90 days, 24% at 180 days, and only 8% at 365 days
(Additional file 1: Appendix Table S1).
Table 3A and 3B provides results for these extensively-
matched treatment groups over the first year after medi-
cation initiation. No significant difference in suicide
death was noted in the primary analysis of all patients
initiating lithium versus valproate (intent-to-treat 0–365
day cOR 1.22, 95% Confidence Interval [CI] 0.82, 1.81;
p = 0.32). In addition, no significant difference was noted
in a secondary analysis among patients during the period
within the first year in which they were still receiving
initial treatment (cOR 0.86, 95% CI 0.46, 1.61; p = 0.63),
nor among patients once they had stopped or modified
lithium, compared to valproate, treatment (OR 1.51, 95%
CI 0.91, 2.50; p = 0.11).
Secondary analyses of briefer treatment intervals
(Table 4A and 4B) indicated an increased intent-to-treat
risk of suicide death among all patients initiating lithium
over 0–180 days that bordered upon, but did not quite
attain, statistically significance (cOR 1.56, 95% CI 0.94,
2.58; p = 0.08), in association with significantly elevated
risk of suicide death among patients after stopping or
modifying lithium, compared to valproate, treatment (OR
2.72, 95% CI 1.21, 6.11; p = 0.015). This differing risk of sui-
cide death between individuals stopping/modifying lithium,
versus stopping/modifying valproate, treatment over 0–180
days was associated almost exclusively with those individ-
uals stopping, rather than modifying, treatment (Table 4,
Footnote i: OR 3.61, 95% CI 1.34, 9.73; p = 0.011).
Figure 2 presents the intent-to-treat survival curve for
suicide death for the lithium and valproate treatment
groups. Because of nonproportional hazards (the cross-
ing of the survival curves at approximately 90 days), the
interpretation of the survival analysis is less straightfor-
ward than, but generally consistent with, the logistic re-
gression results (Additional file 1: Appendix 5).
Table 5 indicates that recent suicidal ideation, when
recorded by diagnostic code, was significantly more
prevalent among patients initiating lithium than among
those initiating valproate (OR 1.30, 95% CI 1.09, 1.54;
p = 0.003), for the 19,411 patients for whom these data
were available.
Discussion
This manuscript reports the largest study, to our know-
ledge, examining lithium’s association with the risk of sui-
cide death. This study is also first to use two design
elements (propensity score matching and intent-to-treat
analysis) intended to help nonrandomized studies better
approximate findings from randomized trials. In this
somewhat distinct sample (a predominantly male Veteran
sample with a broad range of psychiatric diagnoses), no
significant differences in suicide death were observed
Table 2 Characteristics of Patients Initiating Lithium and Valproate (Propensity-score Matched Sample)
Patient characteristic Lithium (n=21194) Valproate (n=21194) Standardized
differenceN (%) N (%)
Demographics
Age ≥50 years olda 10244 48.3 10156 47.9 0.008
Sex (Female)b,c 2894 13.7 2934 13.8 0.005
Race, Whiteb 16748 79.0 16793 79.2 0.005
Race, Blackb 2825 13.3 2770 13.1 0.008
Married 7416 35.0 7298 34.4 0.012
State Suicide Rate, 3rd quintileb 3305 15.6 3251 15.3 0.007
Presenting Diagnosisd (Past 30 days)
Bipolar I Disorderb 9562 45.1 9683 45.7 0.011
Bipolar Disorder, 1643 7.8 1661 7.8 0.003
Not Otherwise Specified (NOS)b
Depressive Disorder, 4214 19.9 4129 19.5 0.010
Not Otherwise Specified (NOS)b
Schizophreniab 924 4.4 949 4.5 0.006
Other Psychosisb 252 1.2 255 1.2 0.001
Additional Psychiatric Diagnoses (Past Year)
Post-Traumatic Stress Disorder (PTSD)b 4842 22.8 4749 22.4 0.010
Alcohol Dependence 4426 20.9 4478 21.1 0.006
Recent Suicidal Behavior Diagnoses (past 30d, by location where diagnosed)
Nonmental Health Hospital-Diagnosed 28 0.13 24 0.11 0.005
Mental Health Hospital-Diagnosed 30 0.14 32 0.15 0.002
Outpatient Visit-Diagnosed 144 0.68 147 0.69 0.002
Recent Suicidal Behavior Diagnoses (past 31-180d, by location where diagnosed)
Nonmental Health Hospital-Diagnosed 43 0.20 43 0.20 0.000
Mental Health Hospital-Diagnosed 31 0.15 29 0.14 0.003
Outpatient Visit-Diagnosed 90 0.42 82 0.39 0.006
Possible Suicidal Behavior-Related Diagnoses (past year)
Any Acute Injury 3872 18.3 3884 18.3 0.001
Recent Discharge from Psychiatric Hospitalization
Discharged in past 7 days 2232 10.5 2219 10.5 0.002
Discharged in past 8-30 days 863 4.1 881 4.2 0.004
Discharged in past 31-180 days 2024 9.5 2063 9.7 0.006
Current Psychiatric Medications
Other Mood Stabilizer(s)b 2891 13.6 2854 13.5 0.005
SSRI antidepressant 7615 35.9 7666 36.2 0.005
SNRI antidepressant 1988 9.4 2019 9.5 0.005
Past Treatment History
Prior Mood Stabilizerb 7503 35.4 7530 35.5 0.003
Diagnoses, Nonpsychiatric (past year)
Mild Liver Diseaseb 1747 8.2 1719 8.1 0.005
Outpatient Utilization, Nonpsychiatric (past 180d)
Gastroenterology Clinic, 1+ visitsb 1102 5.2 1077 5.1 0.005
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Table 2 Characteristics of Patients Initiating Lithium and Valproate (Propensity-score Matched Sample) (Continued)
Current Medications, Nonpsychiatric
Thiazide Diureticb 1499 7.1 1492 7.0 0.001
ACE Inhibitorb 2764 13.0 2736 12.9 0.004
NSAIDsb 3491 16.5 3522 16.6 0.004
aAge presented in this format (< 50 years vs. ≥ 50 years old) to streamline its presentation within this Table. Age was actually modeled using 11 indicator
variables reflecting age groups from < 35 years old, in 5-year intervals, to ≥ 80 years old.
bThis covariate (designated by italics as well as this footnote) had an initial imbalance between the treatment groups of a standardized difference of ≥ 0.10.
Please see Additional file 1: Appendix 2, Table S1 if more detail is desired.
cThe proportion of females in the cohort is low because the Veteran sample is predominantly male.
dPercentages for Indicating Diagnoses do not add up to 100%. Some diagnoses were not substantially imbalanced and therefore not included in the Table,
although they were included in the propensity score and matched upon (e.g. Major Depression, Bipolar II Disorder, Schizoaffective Disorder, and ≥2 Indicating
Diagnoses in past 30 days).
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This lack of association was observed for both the primary
intent-to-treat analyses and for secondary analyses of
patients actively receiving their initial treatment (an effect-
iveness measure traditionally reported in many nonrando-
mized studies of lithium).
This study’s findings diverge from those of some past
meta-analyses [7,29], especially those including nonran-
domized studies [7]. Several potential reasons suggest
themselves. First, follow-up was only continued for one
year (some studies have specifically reported that treat-
ment with lithium for greater than one year was re-
quired to observe significant reductions in suicide risk
[30-32]). A second reason may relate to characteristics
of this sample, including its high rates of treatment dis-
continuation. High rates of treatment discontinuation
would be expected to be especially influential in an
intent-to-treat design, since effect estimates would sub-
stantially reflect risks observed during periods of non-
exposure after discontinuation of treatment. Furthermore,
in naturalistic studies high rates of discontinuation can
complicate the interpretation of risks even among patients
apparently receiving active treatment, since it cannot be
clearly ascertained whether or when patients prescribed
medication actually consume it. Outcomes for patients
who do not start a received prescription or terminate it
early may be ascribed to active treatment, but actually
relate to nonexposure or treatment discontinuation.
Alternatively, some prior studies reporting large associa-
tions between lithium treatment and reduced suicide risk
may have been biased by inadequately controlled initial
confounding or differences in selection occurring during
treatment [10,11].
However, two other possibilities deserve consideration,
since they are consistent with important elements of our
data and would have implications for patients, providers,
and healthcare systems. Both relate to the statistically sig-
nificantly increased suicide risks observed among patients
discontinuing lithium at 0–180 days. Risks among patients
discontinuing treatment may result from several causes,
including: 1) genuine new risks produced by medicationdiscontinuation; and 2) non-treatment-related differences
in inherent suicide risk between the treatment groups (i.e.,
baseline confounding not resolved by the propensity score
matching). A third potential cause, differing tendencies
between the treatment groups for high-risk patients to
discontinue treatment (through self- or provider-based se-
lection), may also contribute to these risks but appears less
likely to explain the entirety of our findings (Additional
file 1: Appendix 6A). If risks observed after lithium dis-
continuation relate directly to discontinuing lithium, this
finding would appear consistent with a substantial literature
documenting pronounced suicide risks upon lithium dis-
continuation (e.g., suicide rates up to 14-fold greater than
during the preceding lithium treatment) [11,12,33]. How-
ever, most of these studies lacked control groups. The only
prior study comparing suicidal behavior risks among pa-
tients discontinuing lithium or discontinuing valproate ob-
served significant increases in suicidal behavior and/or
hospitalization risks among patients discontinuing either
treatment [34]. In our study, increased risks of suicide death
were observed upon discontinuation of lithium, but not
valproate.
The substantial increased risks of suicide death ob-
served among patients discontinuing lithium over 0–180
days could also reflect potential confounding remaining
after propensity score matching [17,35] (i.e., patients ini-
tiating lithium being at higher inherent suicide risk). If
active lithium treatment was associated with reduced
risk of suicide death, then those reduced risks might
largely counterbalance confounding in the intent-to-
treat cohort and among those patients still receiving ini-
tial treatment. Such confounding might then most
clearly manifest as higher suicide risks among lithium-
initiating, compared to valproate-initiating patients, after
treatment discontinuation.
It is unclear whether much confounding persists in
our analysis, given the approximate initial balance ob-
served in numerous measured factors and the further
balance achieved after propensity score matching. Sev-
eral lines of evidence suggest, however, that if any sub-
stantial confounding does exist, it likely biases against
Table 3 Suicide deaths and rates over time by mood stabilizer treatment
A. Primary Analysis (Intent-to-treat, 0–365 days)
All Patients Initiating Treatment (Intent-to-Treat Cohort)
Patients Initiating Lithium Patients Initiating Valproate
Follow-up
Time
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Conditional Odds Ratio
(95% CI)
Rate
Ratio
0-365 days 21194 56 7.27 21194 46 5.98 1.22a (0.82-1.81) 1.22
B. Findings Stratified by Initial Treatment Status (0–365 days)
During Exposure to Initial Treatmentb
Patients Initiating Lithium Patients Initiating Valproate
Follow-up
Time
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Conditional Odds Ratio
(95% CI)
Rate
Ratio
0-365 days 21194 18 6.71 21194 21 7.68 0.86c (0.46-1.61) 0.87
During Period After Stopping/Modifying Initial Treatmentd
Patients Initiating Lithium Patients Initiating Valproate
Follow-up
Time
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Patients,
No.
Suicide
Deaths, No.
Rate (per 106
person-days)
Odds Ratio (95% CI) Rate
Ratio
0-365 days 19494 38 7.58 19362 25 5.05 1.51e (0.91-2.50) 1.50
ap = 0.32.
bThe counts of patients “During Exposure to Initial Treatment” include all the propensity score-matched patients, since all patients accrued at least some
follow-up time in that status. Counts of suicide deaths among these patients indicate suicide deaths occurring on a day in which the patient was classified as still
receiving initial treatment. That is, these counts represent suicide deaths occurring during the period covered by a prescribed supply of medication (without any
co-prescription of the other medication), or during the gap(s) permitted after the prescription had ended, up until the day that the first gap of 15 or more days
had occurred.
cp = 0.63.
dThe counts of patients “During Period After Stopping/Modifying Initial Treatment” indicates all the patients who reach that status by the end of the follow-up
period, since all such patients accrued at least some follow-up time during which they were not still receiving their initially assigned treatment. That is, this is a
count of patients modifying their initial treatment by switching to or augmenting with the other medication or discontinuing their initial treatment, either
temporarily or permanently. Counts of suicide deaths among these patients among these patients indicate suicide deaths occurring on a day after the patient
had exited "During Exposure to Initial Treatment" status, whether by discontinuing or modifying their initial treatment.
ep = 0.11.
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of further increasing covariate balance through propen-
sity score matching was to noticeably reduce initial ef-
fect estimates associating lithium with increased suicide
death risk. This suggests the initial imbalances in pro-
pensity score covariates, although generally small, had
the overall effect of biasing associations towards observ-
ing higher risks for lithium treatment. Any residual (i.e.,
remaining) confounding might plausibly bias in
the same direction, although this cannot be confirmed
with certainty. This bias towards overestimating lithium’s
hazards, to the degree it is present, might arise from the
patients initiating lithium having more severe mental
illness in general, or having a greater prevalence or se-
verity of risk factors for suicide death in particular. Of
note, while our data is extensive, it does not include in-
formation on several important risk factors for suicide
death (e.g., suicidal planning, means, recent stressors,
and psychiatric symptoms, and, for some individuals,
information on suicidal ideation). Our analysis of
diagnostically-coded suicidal ideation found modest but
significantly higher rates among patients initiating lithium,
even after the propensity score matching. This observationis consistent with the possibility that some degree of
remaining confounding exists, biasing towards an overesti-
mate of the risks of suicide death associated with lithium.
A role for chance is also important to consider in
interpreting our findings, since a substantial number of
comparisons were examined and only three statistically
significant associations were observed: among patients
discontinuing lithium compared to valproate over 0–180
days (Table 4B), among all patients initiating lithium
compared to valproate from 91–180 days, and among
patients discontinuing lithium compared to valproate
over 91–180 days (Additional file 1: Appendix 5). Never-
theless, while our primary findings over 0–365 days indi-
cate no statistically significant differences between the
treatments, results from even a study of this size do not
preclude potentially clinically meaningful differences
existing between the treatments below the power of this
study to detect. Furthermore, the significant risks in pa-
tients discontinuing initial lithium treatment over 0–180
days, if not due to chance, generally suggest some de-
gree of nonequivalency between the treatments. These
discontinuation-associated risks suggest that lithium is
associated with either or both of the following: higher
Table 4 Suicide deaths and rates over time by mood stabilizer treatment over briefer time periods (0–90 and 0–180 days)
A. Intent-to-Treat Analyses
All Patients Initiating Treatment (Intent-to-Treat Cohort)
Patients Initiating Lithium Patients Initiating Valproate
Follow-up Time Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Conditional Odds
Ratio (95% CI)
Rate Ratio
0-90 days 21194 18 9.35 21194 19 9.87 0.95a (0.50-1.81) 0.95
0-180 days 21194 39 10.20 21194 25 6.54 1.56b (0.94-2.58) 1.56
B. Findings Stratified by Initial Treatment Status
During Exposure to Initial Treatmentc
Patients Initiating Lithium Patients Initiating Valproate
Follow-up Time Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Conditional Odds
Ratio (95% CI)
Rate Ratio
0-90 days 21194 15 10.00 21194 17 11.30 0.88d (0.44-1.77) 0.88
0-180 days 21194 17 7.99 21194 17 7.93 1.00e (0.51-1.96) 1.01
During Period After Stopping/Modifying Initial Treatmentf
Patients Initiating Lithium Patients Initiating Valproate
Follow-up Time Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Patients, No. Suicide Deaths, No. Rate (per 106
person-days)
Odds Ratio (95% CI) Rate Ratio
0-90 days 11227 3 6.98 11185 2 4.75 1.49g (0.25-8.95) 1.47
0-180 days 16138 22 13.00 15958 8 4.78 2.72h,i (1.21-6.11) 2.72
ap = 0.87.
bp = 0.08.
cSee Table 3, Footnote b.
dp = 0.72.
ep > 0.99.
fSee Table 3, Footnote d.
gp = 0.66.
hp = 0.015.
iRisks observed in patients stopping or modifying initial treatment were almost exclusively observed in patients stopping treatment (rather than modifying
treatment or discontinuing and later resuming either treatment):
Patients Stopping Lithium: Suicides = 18; Suicide Rate (per 106 person-days) = 18.3.
Patients Stopping Valproate: Suicides = 5; Suicide Rate (per 106 person-days) = 5.09.
This yields an odds ratio of 3.61 (95% CI 1.34, 9.73) and a rate ratio of 3.60.
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ation (in contrast to the discontinuation of valproate),
and/or (if some or all of the risks associated with lithium
discontinuation reflect baseline confounding) with
greater positive benefits against suicide death than sug-
gested by our findings.
Additional strengths and limitations
Several study limitations should be noted. Data limita-
tions include gaps in VHA prescription records for inpa-
tients and a lack of information about inpatient and
outpatient care received outside the VHA, and potential
errors in the measurement of covariates. Analytic limita-
tions included the absence of rematching/reweighting of
patients during follow-up. This limitation precluded ana-
lysis of whether patients experiencing suicidal ideation
or behavior during treatment were preferentially discon-
tinued off one of the two treatments, and of whether dif-
ferences existed during follow-up between the treatment
groups in either the initiation of, or persistence with,other psychiatric medications. This study examined typ-
ical care, rather than being restricted to monotherapy,
unlike some recent studies [34,36]. Given that other psy-
chiatric medications may influence the risks of suicide
death [37,38], future studies should consider approaches
which reweight patients during follow-up, such as marginal
structural models (Additional file 1: Appendices 6A and 8).
However, numerous classes of psychiatric medications pre-
scribed at and before lithium or valproate initiation were
very closely balanced between the two treatment groups,
thus likely producing close similarity in concomitant medi-
cations, at least early during follow-up.
In addition, serum medication levels would provide in-
formation separate from prescription data about medica-
tion persistence, and might enhance future analyses if
available. Study findings might have been influenced by
the considerable diagnostic heterogeneity of this patient
cohort, although each individual diagnosis was closely
balanced in prevalence among lithium and valproate re-
cipients and almost 90% of our sample had mood
Figure 2 365-day Survival curve of suicide death by treatment (Intent-to-Treat Analysis).
Smith et al. BMC Psychiatry  (2014) 14:357 Page 11 of 15disorder diagnoses (Additional file 1: Appendix 1). Our
focus upon suicide mortality (comprehensively docu-
mented nationwide, even for patients who leave VHA
care) improved outcome ascertainment compared to
nonfatal suicidal behavior, but unfortunately limited stat-
istical power. This difference in outcome ascertainment
can be substantial: separate studies have estimated that
diagnosed nonfatal suicidal behavior may underestimate
actual nonfatal suicidal behavior by up to 6-fold to 10-
fold [39-41]. This expected underestimate of suicidal
behavior has led us to focus our initial investigation, re-
ported here, upon suicide deaths. Similarly, the V-code
diagnosis of suicidal ideation we used to assess the po-
tential for residual confounding (Table 5) likely captures
only a small fraction of suicidal ideation. However, use
of these codes was intended only as an aid to assess the
potential presence and direction of residual confound-
ing. For this purpose, diagnoses of suicidal ideation, even
if infrequently coded, can provide valuable information,
as has been the case in other studies [42].
Propensity score methods may also potentially inad-
vertently amplify any remaining confounding [23-26]. AsTable 5 Presence of V-code (62.84) denoting suicidal
ideation in the 30 days prior to lithium or valproate
initiation (2005–2008)
Patient
characteristic
Patients
initiating
lithium
Patients
initiating
valproate
Odds ratio
(95% CI)
P value
Suicidal Ideation 305 237 1.30 (1.09-1.54) 0.003
No Suicidal Ideation 9478 9391pointed out above, such confounding could result from
unmeasured differences in mental illness severity or in
suicidal risks factors such as suicidal thinking, impulses,
or intent. Such amplification is exacerbated if variables
are included that are substantially associated with treat-
ment (i.e., lithium or valproate initiation) but not out-
come (i.e., suicide death) [25,26]. How much of a bias is
typically produced is controversial [25,43]. Nevertheless,
the differences between treatment groups in diagnosed
suicidal ideation at baseline suggests some unaddressed
confounding may remain in this study, and our particular
implementation of propensity score matching included ex-
tensive variables in some domains (e.g., medical diagnoses)
in which only a subset of variables may have been strongly
related to suicide risk. (Harris and Barraclough, however,
found that 90% of the medical diagnoses they reviewed
were significantly associated with suicide death risk [44]).
To reduce the potential for amplification of residual con-
founding, we actively evaluated the plausibility of con-
founding for those covariates with particularly substantial
associations with treatment. Furthermore, a sensitivity
analysis targeting this concern by removing a large num-
ber of covariates with the weakest apparent associations
with suicide death from the propensity score produced
only modest effect estimate changes (Additional file 1:
Appendix 7). Most importantly, the direction of change
in the 0–365 day effect estimates from the unmatched
(OR = 1.45) to the matched sample (cOR = 1.22) strongly
suggests that overall confounding was most likely re-
duced by the propensity score matching, not amplified
(Additional file 1: Appendix 6B). Therefore, any
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ficiently minor that the propensity score methodology
still produced an important reduction in overall con-
founding. When comparing this study to other studies,
however, it is important to note that amplification of re-
sidual confounding could have potentially enhanced, to
at least a slight degree, an apparent bias in this study
against observing a protective association between lith-
ium treatment and suicide death.
Generalizability, possible concordance with other recent
studies, and potential “two-sided” benefit/risk aspects
accompanying lithium initiation
Generalizability of this study's findings to non-VHA patients,
to patients with the excluded medical conditions (e.g., cancer,
head injury, or seizures), to cohorts with differing rates of
treatment discontinuation, or to patients that are treated for
longer than one year is uncertain. Nevertheless, our findings
generally agree with recent studies. With one exception [45],
recent nonrandomized studies of suicide or suicidal behavior
risk have observed nonsignificant (and typically modest)
differences between lithium and valproate specifically, or
lithium and anticonvulsants in general [34,36,46-49]. Re-
cently, a small but methodologically-rigorous trial focused
on suicidal behavior prevention [50] observed only
nonsignificant differences in suicidal behavior between
lithium and valproate. Results from this trial (involving
2.5 years of follow-up) and the BALANCE trial [51]
(involving 2 years of follow-up) were combined in the
recent randomized trial meta-analysis [8], which estimated
that lithium treatment was associated with a nonsig-
nificant reduction in nonfatal suicidal behavior compared
to valproate (OR 0.64, 95% CI 0.30-1.36, p = 0.24). Thus,
the study reported here and the recent trials have both
observed nonsignificant intent-to-treat differences be-
tween lithium and valproate in suicide death or suicidal
behavior. The central estimate for lithium’s effect size,
however, did differ in direction between this study (non-
significantly increased risk of suicide death) and the two
trials (nonsignificantly decreased risk of suicidal behavior).
This difference might simply be due to chance, residual
confounding (possibly augmented by residual confounding
amplification), differences in follow-up time (one year ver-
sus 2–2.5 years), or differences in outcome (suicide death
versus suicidal behavior). However, this difference could
also reflect a “two-sided” nature to lithium’s association
with the risk of suicide death/suicidal behavior. That is,
some degree of decreased suicide/suicidal behavior may
be associated with active lithium treatment (thus contrib-
uting more greatly to the intent-to-treat estimates from
the trials, which had much higher treatment persistence
rates), combined with some degree of increased risk asso-
ciated with lithium discontinuation (which would thus
contribute more greatly to the intent-to-treat estimates inour study). A possible “two-sided” association between
lithium and the risk of suicide death would be also
consistent with the significant differences in baseline
suicidal ideation diagnoses between the treatment groups
observed in this study (suggesting some residual confound-
ing and thus a greater benefit to active lithium treatment
than indicated) and the timing of the emergence of signifi-
cant risks after lithium discontinuation (suggesting risks
associated with discontinuation itself) (Additional file 1:
Appendix 6D).
We suspect, although this supposition is inherently some-
what speculative, that the most likely interpretation of our
findings includes both phenomena: some genuine associ-
ation between lithium discontinuation and a short-term in-
crease in the risk of suicide death (compared to valproate
discontinuation), along with some residual confounding
biasing against lithium. (This residual confounding would
imply that active lithium treatment was associated with a
larger decrease in suicide risk than estimated in this study).
This interpretation would imply that it is difficult to deter-
mine whether initiation of lithium in our VHA cohort was
associated with a net reduction or increase in suicide risk
over the first year of treatment. Our data does suggest,
however, that the overall balance of suicide-related risks
and benefits from lithium initiation might be increased if
greater adherence to initial lithium treatment could be
achieved. Research investigating how different health
systems could achieve this goal should be a high
priority. Possible options include group psychoeduca-
tion, which is supported by two clinical trials [52,53].
One of these trials included psychoeducation with other
treatment enhancements including detailed illness and
treatment histories for each patient, follow-up within
2 weeks of hospital discharge, and a post-discharge
“settling in” group [52]. A recent review identified five
evidence-based strategies to boost mood stabilizer adher-
ence, including psychoeducational, cognitive-behavioral,
interpersonal, and family therapy approaches, as well as
systematic care models [54].
Clinical implications of potential discontinuation-associated
risks
Our findings clearly indicate a need for further research of
lithium’s association with suicide death or suicidal behav-
ior (Additional file 1: Appendix 8). Until such research re-
solves the degree to which the increased risks of suicide
death observed in patients discontinuing lithium relate
specifically to lithium discontinuation (rather than con-
founding), prudence suggests patient and provider educa-
tion about the possible risks of treatment discontinuation
and close monitoring of patients discontinuing lithium
(and potentially valproate [36]) when feasible. Such moni-
toring is already recommended to limit mood episode re-
currences [55]. As discussed above, healthcare systems,
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sistence with lithium treatment once initiated. Finally,
when discontinuation does occur, there may be value to
gradually discontinuing lithium when appropriate, given
that gradual discontinuation has been observed to sub-
stantially reduce the risk of mood episode relapse [56,57].
These recommendations concerning the need to minimize
lithium and valproate discontinuation, and any risks
resulting from this discontinuation, may have relevance
well beyond the VHA. The substantial rates of lithium and
valproate discontinuation observed here (median time to
discontinuation of approximately 90 days) may not be
particularly unusual. The observed rates of discontinu-
ation fall within the range provided by the rates of lithium
discontinuation reported for a U.S. health maintenance
organization (median time to discontinuation of approxi-
mately 72 days) [58] and for patients with mood disorders
in Denmark being managed primarily by general practi-
tioners, rather than psychiatrists (median time to discon-
tinuation of approximately 181 days) [59].
Conclusions
In summary, this study did not observe significant bene-
fits for lithium in preventing suicide death compared to
valproate among Veterans Health Administration pa-
tients over the first year of treatment. This study is not-
able, however, for high rates of discontinuation of both
lithium and valproate, and for the finding of increased
suicide risk among patients discontinuing lithium over
0–180 days. If such increased risk largely reflects con-
founding still persisting in the analysis, such confounding
could conceal a clinically meaningful suicide preventative
effect for lithium. Alternatively, some or all of the risk
among patients discontinuing lithium could represent
genuinely greater risks of suicide death related to lithium,
compared to valproate, discontinuation. Until further re-
search more fully clarifies the relationships between lith-
ium treatment, discontinuation, and suicide death, patients
initiating lithium should be educated concerning the pos-
sible risks associated with lithium discontinuation and the
need to maximize persistence with lithium treatment, and
be monitored closely after discontinuation if feasible.
Further research incorporating intent-to-treat approaches
is clearly needed, given the possible beneficial or hazardous
effect sizes still compatible with this study’s results, the
pressing need for interventions against suicide, and the
broad potential use of lithium.Additional file
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